Patent ID: 11911458
Assignee: AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating cells, the method comprising:
(a) positively selecting HIV-specific CD4+ T cells from PBMC isolated from a subject infected with HIV;
(b) contacting the CD4+ T cells with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out ex vivo,
wherein the stimulatory agent comprises a peptide, a mixture of peptides, or a vaccine;

(c) transducing the CD4+ T cells ex vivo with a viral delivery system encoding at least one genetic element, wherein the at least one genetic element comprises (i) a sequence having at least 90% sequence identity with SEQ ID NO: 6, (ii) a sequence having at least 90% sequence identity with SEQ ID NO: 7, and (iii) a sequence having at least 90% sequence identity with SEQ ID NO: 97, wherein the at least one genetic element does not comprise any small RNA targeting HIV sequences other than Vif and Tat; and
(d) culturing the transduced CD4+ T cells for at least 1 day.